EUVIMEDEUVIMED entdecken
Crossref

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M Elli, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola und 13 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025-07 · 25 (7) · e524-e532.e3

DOI: 10.1016/j.clml.2025.02.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-07. Verfasst von Francesca Palandri und 24 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Electronic address: francesca.palandri@unibo.…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In patients with myelofibrosis (MF), overall survival (OS) after ruxolitinib discontinuation is poor, with leukemic transformation, clonal evolution and thrombocytopenia as the main factors worsening prognosis. PATIENTS AND METHODS: To assess the impact of disease phenotype on outcome after ruxolitinib discontinuation in chronic phase patients, we performed a sub-analysis of the "RUX-MF" study (NCT06516406), which now includes 1055 MF patients who received ruxolitinib in a real-life context. RESULTS: After a median follow-up of 3.3 years, 397 patients discontinued ruxolitinib therapy while in chronic phase. At treatment end, 208 patients (52.4%) had a severely cytopenic phenotype (defined as platelets < 100 × 109/L and/or hemoglobin < 8 g/dL); among the remaining myeloproliferative 189 patients, 97 had no cytopenia (51.3%) and 92 (48.7%) had mild anemia only (hemoglobin between 8 and 10 g/dL). Overall, 175 patients (44.1%) had a large splenomegaly (palpable at ≥ 10 cm below costal margin). After ruxolitinib discontinuation, 3-year OS was 33.4% in severely cytopenic and 54.4% in myeloproliferative patients (P < .001); this was confirmed after adjustment for risk categories. Noncytopenic and mildly anemic patients had comparable OS (P = .73). Patients with large splenomegaly had significantly poorer OS compared to nonsplenomegalic patients (OS: 33.5% vs. 51.6% P = .01). Large splenomegaly confirmed its negative prognostic impact on OS of patients with myeloproliferative MF (60.7% vs. 44.5%, P = .05). In patients with severe cytopenia, the presence of a large splenomegaly did not influence OS (41.7% vs. 26.1%, P = .26). CONCLUSIONS: Cytopenic phenotype and large splenomegaly in myeloproliferative MF are key prognostic determinants of outcome after ruxolitinib discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrazolesHumansNitrilesPyrimidinesFemaleMaleAgedMiddle AgedPhenotypePrognosisTreatment OutcomeAged, 80 and overAdult

Stichwörter der Autor:innen

CytopeniaCytoreductive therapyMyeloproliferative neoplasmsOverall survivalSplenomegaly

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazoles

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Electronic address: francesca.palandri@unibo.it.
  • Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
  • Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy.
  • Fondazione IRCCS San Gerardo dei Tintori, divisione di ematologia e unità trapianto di midollo, Monza, Italy.
  • University Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy.
  • Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.

Förderung

  • Ministry of Health

Zitieren

APA

Palandri, F., Breccia, M., Morsia, E., Elli, E. M., Benevolo, G., Tiribelli, M., Beggiato, E., Farina, M., Caocci, G., Pugliese, N., Tieghi, A., Crugnola, M., Binotto, G., Cavazzini, F., Abruzzese, E., Isidori, A., Dedola, A., Iurlo, A., Lemoli, R. M., …, & Branzanti, F. (2025). Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia, 25(7), e524-e532.e3. https://doi.org/10.1016/j.clml.2025.02.015

Vancouver

Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, et al. Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia. 2025;25(7):e524-e532.e3. doi:10.1016/j.clml.2025.02.015

BibTeX
@article{Palandri2025,
  author = {Palandri, Francesca and Breccia, Massimo and Morsia, Erika and Elli, Elena M and Benevolo, Giulia and Tiribelli, Mario and Beggiato, Eloise and Farina, Mirko and Caocci, Giovanni and Pugliese, Novella and Tieghi, Alessia and Crugnola, Monica and Binotto, Gianni and Cavazzini, Francesco and Abruzzese, Elisabetta and Isidori, Alessandro and Dedola, Alessandra and Iurlo, Alessandra and Lemoli, Roberto M and Cilloni, Daniela and Bocchia, Monica and Heidel, Florian H and Bonifacio, Massimiliano and Palumbo, Giuseppe A and Branzanti, Filippo},
  title = {Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  volume = {25},
  number = {7},
  pages = {e524--e532.e3},
  doi = {10.1016/j.clml.2025.02.015}
}
Kostenlos starten →